Novel cytostatic 7-deazapurine nucleosides
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F18%3A00499653" target="_blank" >RIV/61388963:_____/18:00499653 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=EP&NR=3133080B1&KC=B1&FT=D&ND=4&date=20180801&DB=&locale=en_EP#" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?CC=EP&NR=3133080B1&KC=B1&FT=D&ND=4&date=20180801&DB=&locale=en_EP#</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Novel cytostatic 7-deazapurine nucleosides
Original language description
The invention provides compounds of formula I, wherein R 1 and R 2 have any of the values defined in the specification and salts thereof, as well as compositions comprising such compounds and therapeutic methods that utilize such compounds.
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10401 - Organic chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
EP3133080
Publisher
EPO_1 -
Publisher name
European Patent Office
Place of publication
Munich, The Hague, Berlin, Vienna, Brussels
Publication country
—
Date of acceptance
Aug 1, 2018
Owner name
Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
A - Výsledek využívá pouze poskytovatel
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence